Kyverna rises on stiff person syndrome data

Kyverna rises on stiff person syndrome data

Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.

Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition called stiff person syndrome that has no approved therapies.

Kyverna (NASDAQ:KYTX) Reports Positive Phase 2 Data for CAR T Therapy in Stiff Person Syndrome

Kyverna (NASDAQ:KYTX) Reports Positive Phase 2 Data for CAR T Therapy in Stiff Person Syndrome

Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial

Kyverna Therapeutics' CAR-T therapy succeeded in a key study in stiff person syndrome, a rare autoimmune disorder that leads to painful muscle spasms and stiffness. The California biotech said Monday that ...